Demographic and clinical features at diagnosis of 617 patients with PMF subdivided according to their genotype (JAK2, CALR, and MPL mutation status)
| . | JAK2 (V617F)-mutant patients . | CALR-mutant patients . | MPL-mutant patients . | Patients with nonmutated JAK2, CALR, and MPL (triple-negative subjects) . | P . |
|---|---|---|---|---|---|
| No. (%) | 399 (64.7%) | 140 (22.7%) | 25 (4.0%) | 53 (8.6%) | |
| Sex (male/female) | 266/133 | 77/63 | 17/8 | 34/19 | .101 |
| Age at onset, median (range), y | 63 (18-91) | 50 (26-83) | 64 (31-84) | 67 (31-88) | <.001 |
| Hemoglobin, median (range), g/dL | 12 (3-19.6) | 11.7 (7.1-15.9) | 11 (6.5-15) | 9.9 (5-19) | <.001 |
| WBC count, median (range), ×109/L | 10 (1.6-106.2) | 8.2 (2.2-45) | 8.4 (2.1-20.3) | 8.4 (2.4-90.8) | .002 |
| PLT count, median (range), ×109/L | 310 (25-1963) | 509 (46-1563) | 307 (53-958) | 175 (19-3279) | <.001 |
| Circulating blasts, median (range), % | 0 (0-20) | 0 (0-10) | 0 (0-4) | 0 (0-16) | <.001 |
| Lactate dehydrogenase, median (range), mU/mL | 553 (149-3440) | 692 (203-3610) | 580 (183-2291) | 531 (160-3173) | .208 |
| Circulating CD34+ cells, median (range), ×106/L | 16.2 (0.8-1190) | 34.2 (1.7-1902) | 100 (6.3-506.3) | 45.3 (1.6-485.5) | .022 |
| IPSS risk group, % | |||||
| Low | 31 | 51 | 28 | 10 | <.001 |
| Intermediate 1 | 31 | 23 | 36 | 26 | |
| Intermediate 2 | 22 | 18 | 24 | 17 | |
| High | 16 | 8 | 12 | 47 |
| . | JAK2 (V617F)-mutant patients . | CALR-mutant patients . | MPL-mutant patients . | Patients with nonmutated JAK2, CALR, and MPL (triple-negative subjects) . | P . |
|---|---|---|---|---|---|
| No. (%) | 399 (64.7%) | 140 (22.7%) | 25 (4.0%) | 53 (8.6%) | |
| Sex (male/female) | 266/133 | 77/63 | 17/8 | 34/19 | .101 |
| Age at onset, median (range), y | 63 (18-91) | 50 (26-83) | 64 (31-84) | 67 (31-88) | <.001 |
| Hemoglobin, median (range), g/dL | 12 (3-19.6) | 11.7 (7.1-15.9) | 11 (6.5-15) | 9.9 (5-19) | <.001 |
| WBC count, median (range), ×109/L | 10 (1.6-106.2) | 8.2 (2.2-45) | 8.4 (2.1-20.3) | 8.4 (2.4-90.8) | .002 |
| PLT count, median (range), ×109/L | 310 (25-1963) | 509 (46-1563) | 307 (53-958) | 175 (19-3279) | <.001 |
| Circulating blasts, median (range), % | 0 (0-20) | 0 (0-10) | 0 (0-4) | 0 (0-16) | <.001 |
| Lactate dehydrogenase, median (range), mU/mL | 553 (149-3440) | 692 (203-3610) | 580 (183-2291) | 531 (160-3173) | .208 |
| Circulating CD34+ cells, median (range), ×106/L | 16.2 (0.8-1190) | 34.2 (1.7-1902) | 100 (6.3-506.3) | 45.3 (1.6-485.5) | .022 |
| IPSS risk group, % | |||||
| Low | 31 | 51 | 28 | 10 | <.001 |
| Intermediate 1 | 31 | 23 | 36 | 26 | |
| Intermediate 2 | 22 | 18 | 24 | 17 | |
| High | 16 | 8 | 12 | 47 |